Shares in Basilea Pharmaceutica AG dropped by more than 36 percent Tuesday on news that European Union (EU) approval of Zevtera (ceftobiprole), expected during the current quarter, would be delayed until at least the year end. (BioWorld International)

No Abstract BioWorld International CorrespondentDUBLIN, Ireland - Opsona Therapeutics Ltd. raised €18 million (US$23 million) in a Series B round and unveiled a research and collaboration agreement with CSL Ltd., based on the identification of novel vaccine adjuvant formulations using its proprietary OpsoVac immunotherapy platform.